Masood Khan joins KCAS team
Becomes senior director of ligand binding assay services
For nearly 20 years, Dr Khan has led wide-ranging research on strategic planning for LBA programmes, as well as the development of GLP-compliant and non-GLP assays for the conduct of ligand binding studies. He has chaired and organised many conferences and lectures at annual forums and meetings of the American Association of Pharmaceutical Scientists’ (AAPS) and has helped establish the LBAB-Focus Group, a specialist division of AAPS.
Dr Khan has worked in executive capacities for several contract research organisations (CROs) and pharmaceutical companies including MDS Life Sciences, Covance, NeuroBiotech, Medlmmune and most recently the National Institute of Health.
Dr Khan received his PhD in biochemistry from Aligarh University, India, and has conducted post-doctoral studies at the National Institute of Environmental Health Sciences in North Carolina and McGill University, Royal Victoria Hospital in Canada.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing]()
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Precise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Ingredients
![UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny]()
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny
The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Manufacturing
![Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India]()
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Packaging
![Embracing healthcare innovation with 2D codes]()
Embracing healthcare innovation with 2D codes
Pharmaceutical manufacturers already serialise medicines using 2D codes to meet regulatory requirements, but a 2D code can be so much more than a tick box for compliance, explains Ian Chapman, Strategic Manager for Digital Coding at Domino Printing Sciences
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
